CoChat

Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC–HOVON randomized phase III study (06914)

Sonneveld, P., Suciu, S., Weijermans, P., Beksac, M., Neuwirtova, R., Solbu, G., Lokhorst, H., Van Der Lelie, J., Dohner, H., Gerhartz, H., Segeren, C. M., Willemze, R., Lowenberg, B. · 2001 · British Journal of Haematology
Cited by 93

The DOI matches its Crossref record.

Abstract

Patients with multiple myeloma (MM) refractory to alkylating agents frequently express P‐glycoprotein (Pgp), which is associated with the multidrug resistance (MDR) phenotype. We have conducted a randomized phase II/III study of the MDR reversal agent cyclosporin A combined with VAD (vincristine, doxorubicin, dexamethasone) compared with standard VAD in patients with MM stage IIA/IIIA who were refractory to or progressive after treatment with alkylating agents. Out of 81 patients who were randomized, 75 were eligible and evaluable: 34 in the VAD + cyclosporin A arm versus 41 in the VAD arm. Toxicities of grade 2–3 were observed more often with VAD + cyclosporin A than with VAD only: nausea (30% versus 8%, P = 0·015), mucositis (18% versus 5%, P = 0·13), infection (45% versus 35%, P = 0·50). The treatment results were similar in the two arms: 53% versus 49% responded [95% CI (−18·5%, 26·9%)]. The median progression‐free survival (PFS) was 8·6 months (VAD + cyclosporin A) versus 5·8 months (VAD): [log rank P = 0·16, hazard ratio = 0·71, 95% CI (0·44, 1·15)], and median overall survival was 13 months versus 14·6 months [log rank P = 0·89, hazard ratio = 0·96, 95% CI (0·62, 1·72)]. The cause of death was progressive disease (85%), toxicity (10%) or other (5%). Bone marrow analysis performed in 23 patients showed that the response rate was 67% in Pgp‐positive versus 55% in Pgp‐negative patients. Cyclosporin A combined with VAD is relatively well tolerated. There is no effect of cyclosporin A on the overall response rate, PFS and overall survival with VAD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2141.2001.03171.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 93

Metadata

Authors
Sonneveld, P., Suciu, S., Weijermans, P., Beksac, M., Neuwirtova, R., Solbu, G., Lokhorst, H., Van Der Lelie, J., Dohner, H., Gerhartz, H., Segeren, C. M., Willemze, R., & Lowenberg, B.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2001-12
Volume
115
Issue
4
Pages
895-902
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W1972960351
Cited by
93
References
0
FWCI
1.96
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC–HOVON randomized phase III study (06914). https://app.cochat.ai/papers/10.1046/j.1365-2141.2001.03171.x
The paper
Sonneveld, P., Suciu, S., Weijermans, P., Beksac, M., Neuwirtova, R., Solbu, G., Lokhorst, H., Van Der Lelie, J., Dohner, H., Gerhartz, H., Segeren, C. M., Willemze, R., & Lowenberg, B. (2001). Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC–HOVON randomized phase III study (06914). British Journal of Haematology. https://doi.org/10.1046/j.1365-2141.2001.03171.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.